These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake. Ostwal V; Basu S; Bhargava P; Shah M; Parghane RV; Srinivas S; Chaudhari V; Bhandare MS; Shrikhande SV; Ramaswamy A Neuroendocrinology; 2021; 111(10):998-1004. PubMed ID: 33017827 [TBL] [Abstract][Full Text] [Related]
23. Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience. Grewal US; Loeffler BT; Paschke A; Dillon JS; Chandrasekharan C J Gastrointest Cancer; 2024 Sep; 55(3):1165-1170. PubMed ID: 38780680 [TBL] [Abstract][Full Text] [Related]
24. Clinical utility of Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622 [TBL] [Abstract][Full Text] [Related]
25. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of Adnan A; Basu S J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476 [TBL] [Abstract][Full Text] [Related]
26. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056 [TBL] [Abstract][Full Text] [Related]